{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jackson S"],"funding":["British Heart Foundation","Medical Research Council","National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["655-668"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616636"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(7)"],"pubmed_abstract":["<h4>Background</h4>A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×10<sup>1</sup> 50% tissue culture infectious dose (TCID<sub>50</sub>) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2, a CHIM that could be used for vaccine development will need to induce infection in those with pre-existing immunity. Our aim was to find a dose of pre-alpha SARS-CoV-2 virus that induced infection in previously infected individuals.<h4>Methods</h4>Healthy, UK volunteers aged 18-30 years, with proven (quantitative RT-PCR or lateral flow antigen test) previous SARS-CoV-2 infection (with or without vaccination) were inoculated intranasally in a stepwise dose escalation CHIM with eith"],"journal":["The Lancet. Microbe"],"pubmed_title":["Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study."],"pmcid":["PMC7616636"],"funding_grant_id":["MR/X009297/1","222305/Z/21/Z","NIHR300791","CH/16/1/32013","222305"],"pubmed_authors":["Fredsgaard-Jones TPW","Sodipo V","Longet S","Sette A","Carroll M","Patel B","Pollard AJ","Catchpole A","Conway O","Luciw M","COV-CHIM01 study team","Harris SA","Parvelikudy B","Marshall JL","Hughes E","Benamore R","Alparaque M","Tipton T","Voaides A","Orobiyi-Rieba M","Platt A","Laidlaw S","Mujadidi Y","Valmores MA","Morrison H","Cabrera Puig I","Breuer J","Lopez-Ramon R","Tanner R","Barnes E","Gleeson F","Quaddy J","Vuddamalay G","Stone H","Preston-Jones H","Byard N","Turner C","Crowther C","Doherty RP","Rapeport G","Ferreira VM","Mawer A","Nehiweze A","Nyamunda S","Ateere A","Satti I","Pswarayi D","Bharti N","Jackson S","McShane H","Mitchell R","Chiu C","Srijith P","Dunachie SJ","Stylianou E","Wu MS","Samuel BE","Burns A","Jose J","Cooper C","Anid L","Johnstone T"],"additional_accession":[]},"is_claimable":false,"name":"Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.","description":"<h4>Background</h4>A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×10<sup>1</sup> 50% tissue culture infectious dose (TCID<sub>50</sub>) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2, a CHIM that could be used for vaccine development will need to induce infection in those with pre-existing immunity. Our aim was to find a dose of pre-alpha SARS-CoV-2 virus that induced infection in previously infected individuals.<h4>Methods</h4>Healthy, UK volunteers aged 18-30 years, with proven (quantitative RT-PCR or lateral flow antigen test) previous SARS-CoV-2 infection (with or without vaccination) were inoculated intranasally in a stepwise dose escalation CHIM with eith","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T07:33:18.135Z","creation":"2025-04-04T23:48:22.669Z"},"accession":"S-EPMC7616636","cross_references":{"pubmed":["38703782"],"doi":["10.1016/S2666-5247(24)00025-9"]}}